Conference abstract · 2018
Conference abstractPublished 13 Oct 2016
The story of Copaxone (glatiramer acetate) in the treatment of multiple sclerosis and its new applications
The Weizmann Institute of Science, Israel
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Multiple sclerosis (MS) is currently recognized as complex diseases in which inflammatory autoimmune reactivity in the central nervous system (CNS) results in demyelination, axonal and neuronal pathology. Novel treatment strategies aim to reduce the detrimental inflammation and induce neuroprotective repair processes. The synthetic copolymer Copaxone (glatiramer acetate, GA), an approved drug for the treatment of MS, is the first and so far the only therapeutic agent to have a copolymer as its active ingredient. Using the animal model of MS experimental autoimmune encephalomyelitis (EAE), the immunomodulatory mechanism of action of GA was elucidated. It was found that GA treatment induces immunomodulatory shift from the inflammatory towards the anti-inflammatory pathways. Furthermore, recent studies revealed neuroprotective and repair consequences of GA treatment in the CNS. These include elevation in neurotrophic factors expressions, remyelination and neurogenesis. Based on its immunomodulatory mode of action, additional potential applications of GA were investigated, such as prevention of immune rejection, improvement of stem cells engraftment and amelioration of inflammatory bowel diseases (IBD).
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 1 Dec 2016
The story of glatiramer acetate (Copaxone) in the treatment of multiple sclerosis - The potential for neuroprotection by immunomodulat
Conference abstract
From basic research to drug development: The story of Copaxone (glatiramer acetate) in the treatment of multiple sclerosis and its new Applications
Conference abstract · 2018
FROM BASIC RESEARCH TO DRUG DEVELOPMENT: THE STORY OF COPAXONE (GLATIRAMER ACETATE) IN THE TREATMENT OF MULTIPLE SCLEROSIS AND POTENTIAL APPLICATIONS FOR ADDITIONAL PATHOLOGIES
Conference abstract · 1 Dec 2016
The story of Glatiramer acetate (Copaxone) in the treatment of multiple sclerosis: The potential for neuroprotection by immunomodulatory treatment
More from this journal
The newest in Immunome Research.
Short communication · 29 Dec 2025
Beyond the Surface: Cellular Immune Responses in Uncharted Territories
Commentary · 27 Dec 2025
Stress-Induced Remodeling of Immune Cell Phenotypes
Perspective · 26 Dec 2025
Immune System Dysregulation in Complex Multisystem Disorders
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalImmunome Research
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Rina Aharoni”

